We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -4.25531914894 | 2.82 | 2.94 | 2.51 | 1333911 | 2.68565007 | CS |
4 | 0.04 | 1.5037593985 | 2.66 | 3.305 | 2.44 | 1701749 | 2.85633987 | CS |
12 | -0.15 | -5.26315789474 | 2.85 | 3.305 | 2.41 | 1920701 | 2.82563973 | CS |
26 | 0.35 | 14.8936170213 | 2.35 | 3.45 | 1.96 | 2115232 | 2.70370584 | CS |
52 | 0.44 | 19.4690265487 | 2.26 | 3.45 | 1.51 | 1647804 | 2.46541039 | CS |
156 | -15.44 | -85.1157662624 | 18.14 | 18.34 | 1.51 | 1031451 | 4.07011506 | CS |
260 | -13.2 | -83.0188679245 | 15.9 | 24.47 | 1.51 | 964553 | 4.76386877 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions